COPD is the sixth approved indication for the interleukin-4 receptor alpha antagonist monoclonal antibody. Credits: Wildflower_macro/Shutterstock.com With the latest nod from the US Food and
VTX3232 is under development for potential uses across several neuroinflammatory and neurodegenerative conditions. Credits: rafapress/Shutterstock.com Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate
Unlike Comirnaty and Spikevax, Kostaive is designed as a sa-mRNA vaccine which should boost a stronger response. Credits: Pormezz/Shutterstock.com CSL and Arcturus Therapeutics’s self-amplifying mRNA
RGX-121 is a gene therapy designed to deliver a functional copy of the IDS gene to the central nervous system via the NAV AAV9 vector.
Nipocalimab is an IgG receptor FcRn large subunit p51 antagonist designed to compete with IgG in binding to FcRn. Credits: Skorzewiak/Shutterstock.com Johnson & Johnson (J&J)
MSD’s Winrevair has been approved to treat pulmonary arterial hypertension (PAH), a disorder which is caused by high blood pressure in the lungs. Credits: MMD
Pfizer and BioNTech have announced that a Phase III trial studying their investigational combination mRNA vaccine for the treatment of influenza and Covid-19 has failed
Pfizer’s RSV vaccine Abrysvo is expected to generate global sales of $2.6bn in 2030. Credit: Art_Photo / Shutterstock.com Pfizer has announced positive topline results from
CN201 is a T cell engager bispecific antibody in development for the treatment of B cell non-Hodgkin lymphoma (B-NHL) and B cell acute lymphoblastic leukemia
Leqembi is an anti-amyloid treatment designed to ablate amyloid-beta aggregates, which are a major driver of Alzheimer’s disease. Credits: joshimerbin/Shutterstock.com Eisai has announced that patients